The European Union health agency on Monday warned that Europe was set to miss goals on reducing the use of antibiotics, ...

Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...

The European Medicines Agency (EMA) says it has been hit by a cyber-attack and documents relating to a Covid-19 vaccine have been accessed. BioNTech, which makes one of the vaccines in partnership ...

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

The European Commission (EC) will decide in approximately two months. Last month, Novartis released new data from the ALITHIOS open-label extension study. Data show first-line Kesimpta (ofatumumab ...

Underwritten Produced with financial support from an organization or individual ... Additionally, the FAMHP works closely with the European Medicines Agency (EMA) and the competent authorities ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...

Patient involvement in health policy is a patchwork across the EU. Putting the lived experience front and centre of policy-making was prioritised at a recent high-level policy event organised by the ...

The EMA sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.